Katlama, Christine

Polylactic acid implants (New-Fill)® to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA

Valantin, M.-A., Aubron-Olivier, C., Ghosn, J., Laglenne, E., Pauchard, M., Schoen, H., Bousquet, R., Katz, P., Costagliola, D., & Katlama, C. (2003) · AIDS

Facial Rejuvenation and Surgery TechniquesHIV-related health complications and treatments

Cited by 355

European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV*

Lundgren, J., Battegay, M., Behrens, G., De Wit, S., Guaraldi, G., Katlama, C., Martinez, E., Nair, D., Powderly, W., Reiss, P., et al. (2008) · HIV Medicine

HIV-related health complications and treatmentsDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 210

Acute hepatitis C in HIV-infected men who have sex with men.

Ghosn, J., Pierre‐François, S., Thibault, V, Duvivier, C., Tubiana, R., Simon, A., Valantin, M., Dominguez, S., Caumes, E., & Katlama, C. (2004) · HIV Medicine

Hepatitis C virus researchHIV, Drug Use, Sexual Risk

Cited by 111

Lymphopenia-driven homeostatic regulation of naive T cells in elderly and thymectomized young adults

Sauce, D., Larsen, M., Fastenackels, S., Roux, A., Gorochov, G., Katlama, C., Sidi, D., Sibony-Prat, J., & Appay, V. (2012) · The Journal of Immunology

T-cell and B-cell ImmunologyPsoriasis: Treatment and Pathogenesis

Cited by 82

Bone mineral density and inflammatory and bone biomarkers after darunavir–ritonavir combined with either raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults with HIV-1: A substudy of the NEAT001/ANRS143 randomised trial

Bernardino, J. I., Mocroft, A., Mallon, P. W., Wallet, C., Gerstoft, J., Russell, C., Reiss, P., Katlama, C., De Wit, S., Richert, L., et al. (2015) · The Lancet HIV

HIV-related health complications and treatmentsHIV/AIDS drug development and treatment

Cited by 76

High clustering of acute HCV infections and high rate of associated STIs among Parisian HIV-positive male patients.

Todesco, E., Day, N., Amiel, C., Elaerts, S., Schneider, V., Roudière, L., Hué, S., Liotier, J.-Y., Bottero, J., L'Yavanc, T., et al. (2019) · International Journal of Antimicrobial Agents

Hepatitis C virus researchHIV, Drug Use, Sexual Risk

Cited by 7

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial

Moyle, G., Assoumou, L., de Castro, N., Post, F. A., Curran, A., Rusconi, S., De Wit, S., Stephan, C., Raffi, F., Johnson, M., et al. (2024) · The Lancet HIV

HIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Cited by 6

False-negative Results of Human Immunodeficiency Virus (HIV) Rapid Testing in HIV Controllers

Hage-Sleiman, M., Tremeaux, P., Fillion, M., Boufassa, F., Melard, A., Gardiennet, E., Mariaggi, A.-A., Plantier, J.-C., Rouzioux, C., Lambotte, O., et al. (2020) · Clinical Infectious Diseases

HIV Research and TreatmentHIV/AIDS Research and Interventions

Cited by 2